Explore 3 Stock Ideas & Industry Insights Download Free Report

Stocks

Goldman Sachs in talks to transfer GM credit-card partnership to Barclays, WSJ reports

(Reuters) - Goldman Sachs is in talks to transfer its General Motors credit-card program to Barclays, the Wall Street Journal reported on Monday, citing people familiar with the matter. Barclays is the leading candidate to take over issuance of the credit cards, which have …

EODHD | 29 April 2024

Those who invested in Reliance Worldwide (ASX:RWC) a year ago are up 27%

Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than that by picking better than average stocks (as part of a diversified portfolio). To wit, the Reliance Worldwide Corporation Limited (ASX:RWC) share price is …

EODHD | 29 April 2024

30 Largest Software Companies in the World by Market Cap

In this article, we will look into the 30 largest software companies in the world by market cap. If you want to skip our detailed analysis, you can go directly to the 5 Largest Software Companies in the World by Market Cap. Software Industry …

EODHD | 29 April 2024

Rambus (RMBS) Q1 Earnings and Revenues Beat Estimates

Rambus (RMBS) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.44 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

EODHD | 29 April 2024

FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer

TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer Conversion to full approval from accelerated approval is based on positive results from global Phase 3 study demonstrating overall survival benefit …

EODHD | 29 April 2024

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy TIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark, April 29, 2024--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) …

EODHD | 29 April 2024

Transocean (RIG) Reports Q1 Loss, Misses Revenue Estimates

Transocean (RIG) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents …

EODHD | 29 April 2024

Crown (CCK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Crown Holdings (CCK) reported $2.78 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 6.4%. EPS of $1.02 for the same period compares to $1.20 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $2.93 …

EODHD | 29 April 2024

NRG Energy (NRG) Surpasses Market Returns: Some Facts Worth Knowing

NRG Energy (NRG) ended the recent trading session at $73.95, demonstrating a +1.57% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.32%. Meanwhile, the Dow gained 0.38%, and the Nasdaq, a tech-heavy index, …

EODHD | 29 April 2024

Best Buy (BBY) Stock Sinks As Market Gains: Here's Why

Best Buy (BBY) closed the latest trading day at $75, indicating a -0.07% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.32%. Meanwhile, the Dow experienced a rise of 0.38%, and the technology-dominated Nasdaq …

EODHD | 29 April 2024
Support

Hi! How can we help you today?

Loading…